

Ajanta Pharma Announces the Launch of Voriconazole Tablets

Bridgewater, NJ – (November 7, 2016) – Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, India, announces today the launch of Voriconazole Tablets (50mg, 200mg), a bioequivalent generic version of Vfend®¹, into the US market.

Voriconazole Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 29 Abbreviated New Drug Applications (ANDAs) of which it has 16 final ANDA approvals; 2 tentative approvals; and 11 ANDAs under review with the United States Food & Drug Administration.

About Ajanta Pharma

Ajanta Pharma Limited is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing, and marketing quality, finished pharmaceuticals across 30+ countries.

For the financial year ended March 31, 2016, Ajanta's consolidated revenue stood at \$261 million and net profit of \$61 million. For the last five years, Ajanta has posted healthy performance with its consolidated revenue growing at 26% CAGR and net profit at 51% CAGR.

For more details about Ajanta Pharma USA Inc., please visit us at www.ajantapharmausa.com.

¹ Vfend® is a registered trademark of PF Prism CV

For more information, please contact:

John Adams
john.adams@ajantapharma.com
908.252.1165